Impact of RSV Vaccines and Nirsevimab on Reducing Hospitalizations in Infants

Recent research indicates that maternal respiratory syncytial virus (RSV) vaccination and administration of nirsevimab are associated with a significant decrease in RSV-related hospitalizations among infants aged 0 to 7 months during the 2024–2025 season. This season marked the first with widespread availability of both prevention methods. A study published in the CDC's Morbidity and Mortality Weekly Report analyzed data from national surveillance networks, comparing hospitalization rates across different seasons. The findings revealed that infants in this age group experienced an estimated 43% to 28% reduction in RSV hospitalization rates, with the most notable decline—up to 52%—observed in those aged 0 to 2 months, especially during peak months from December to February.

These results underscore the importance of strategic health planning to implement the CDC’s recommendations for RSV prevention, enabling parents to protect their infants early in the RSV season. For infants born during the season, ensuring timely administration of nirsevimab within the first week of life—preferably during birth hospitalization—is crucial for those not covered by maternal vaccination. These preventive strategies aim to safeguard infants from severe RSV illness, reducing healthcare burdens and improving infant health outcomes.

Source: https://medicalxpress.com/news/2025-05-rsv-vaccines-nirsevimab-linked-hospitalization.html